Acasti Pharma Inc. announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial?NCT05995405) has been accepted for presentation at the 2024 International Stroke Conference, to be held February 7 to 9, 2024 in Phoenix, AZ. The STRIVE-ON trial is a prospective, open-label, randomized (1:1 ratio), parallel group trial of GTX-104 compared with oral nimodipine, in patients hospitalized for aSAH. Key trial design features include: Approximately 100 patients are expected to be enrolled at an estimated 25 hospitals in the U.S.; The primary endpoint is safety and will be measured as comparative adverse events, including hypotension, between the two groups; GTX-104 will be administered as a continuous IV infusion of 0.15 mg/hour, and a 30-minute IV bolus of 4 mg every 4 hours.

Oral nimodipine will be administered as 60 mg (two 30 mg capsules) every 4 hours; Both groups will receive their assigned GTX-104 or oral nimodipine for up to 21 consecutive days and will be evaluated from commencement of patient treatment through a 90-day follow-up period.